GoAI
Get started
Co-Diagnostics, Inc. logo

Co-Diagnostics, Inc.

CODX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.21

+$0.06 · +5.22%

Aug 21, 4:00 PM ET

CODX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

43

Fair Value

Momentum

16

Strong Down

Sentiment

57

Mixed

Risk resilience

18

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Dwight Egan
Listed since
Jul 12, 2017
Employees
115

Market position

Day range

Current $1.21

52-week range

Current $1.21

Open
$1.18
Previous close
$1.15
Volume
293.3K
0.07× average
Average volume
4.12M
Average daily volume
Market cap
1.35M USD
Beta
2.88
Market reference 1
50-day average
$2.3529
-48.57% below average
200-day average
$4.1466
-70.82% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-3.9M USD
P/E (TTM)
-0.05×
P/B (TTM)
0.41×
P/S (TTM)
1.87×
EV / EBITDA
0.08×
Earnings yield
-695.36%
Free cash flow yield
-442.42%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
8.07%
Operating margin
-4170.14%
Net margin
-6523.04%
Return on equity
-227.33%
Return on assets
-189.54%
Return on invested capital
-138.31%

Financial health

Debt / equity
0.14×
Current ratio
3.87×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends850%-2198%-5247%-8296%Gross margin, FY2021: 88.18%Gross margin, FY2022: 83.98%Gross margin, FY2023: 38.57%Gross margin, FY2024: 74.48%Gross margin, FY2025: 64.28%Operating margin, FY2021: 47.06%Operating margin, FY2022: -78.85%Operating margin, FY2023: -626.92%Operating margin, FY2024: -1023.75%Operating margin, FY2025: -5025.53%Net margin, FY2021: 37.45%Net margin, FY2022: -41.61%Net margin, FY2023: -518.68%Net margin, FY2024: -961.37%Net margin, FY2025: -7533.62%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 88.18%. Gross margin FY2022 83.98%. Gross margin FY2023 38.57%. Gross margin FY2024 74.48%. Gross margin FY2025 64.28%. Operating margin FY2021 47.06%. Operating margin FY2022 -78.85%. Operating margin FY2023 -626.92%. Operating margin FY2024 -1023.75%. Operating margin FY2025 -5025.53%. Net margin FY2021 37.45%. Net margin FY2022 -41.61%. Net margin FY2023 -518.68%. Net margin FY2024 -961.37%. Net margin FY2025 -7533.62%.

Income trends

Revenue

622.49K USD-84.10%

Operating income

−31.28M USD+21.95%

Net income

−46.9M USD-24.59%
Income trends across reported periods112.36M USD54.45M USD−3.46M USD−61.37M USDRevenue, FY2021: 97.89M USDRevenue, FY2022: 34.22M USDRevenue, FY2023: 6.81M USDRevenue, FY2024: 3.92M USDRevenue, FY2025: 622.49K USDOperating income, FY2021: 46.06M USDOperating income, FY2022: −26.98M USDOperating income, FY2023: −42.71M USDOperating income, FY2024: −40.08M USDOperating income, FY2025: −31.28M USDNet income, FY2021: 36.66M USDNet income, FY2022: −14.24M USDNet income, FY2023: −35.33M USDNet income, FY2024: −37.64M USDNet income, FY2025: −46.9M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 97.89M USD. Revenue FY2022 34.22M USD. Revenue FY2023 6.81M USD. Revenue FY2024 3.92M USD. Revenue FY2025 622.49K USD. Operating income FY2021 46.06M USD. Operating income FY2022 −26.98M USD. Operating income FY2023 −42.71M USD. Operating income FY2024 −40.08M USD. Operating income FY2025 −31.28M USD. Net income FY2021 36.66M USD. Net income FY2022 −14.24M USD. Net income FY2023 −35.33M USD. Net income FY2024 −37.64M USD. Net income FY2025 −46.9M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue622.49K USD3.92M USD6.81M USD34.22M USD97.89M USD
Cost of goods sold222.38K USD999.12K USD4.18M USD5.48M USD11.57M USD
Gross profit400.11K USD2.92M USD2.63M USD28.74M USD86.31M USD
Research and development19.14M USD20.98M USD22.96M USD17.44M USD14.96M USD
Selling, general, and administrative11.44M USD20.64M USD21.14M USD21.61M USD24.95M USD
Operating expenses31.68M USD43M USD45.33M USD55.72M USD40.25M USD
Interest income292.93K USD1.09M USD1.16M USD704.05K USD45.63K USD
Depreciation and amortization1.11M USD1.38M USD1.23M USD1.28M USD335.36K USD
Operating income−31.28M USD−40.08M USD−42.71M USD−26.98M USD46.06M USD
Net income−46.9M USD−37.64M USD−35.33M USD−14.24M USD36.66M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
-329.09%
11 comparable reports
Latest EPS result
-1.46
Estimate -3 · Beat by 51.33%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.28-6.06-11.85-17.63Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -10.81, estimate -0.33, surprise -3175.76%, Miss. Q2 2025, reported May 8, 2025: actual -7.21, estimate -8.1, surprise +10.99%, Beat. Q3 2025, reported Aug 14, 2025: actual -6.91, estimate -7.51, surprise +7.99%, Beat. Q4 2025, reported Nov 13, 2025: actual -4.8, estimate -5.71, surprise +15.94%, Beat. Q1 2026, reported Mar 31, 2026: actual -16.35, estimate -3.6, surprise -354.17%, Miss. Q2 2026, reported May 14, 2026: actual -4.06, estimate -3.75, surprise -8.27%, Miss. Q3 2026, reported Aug 13, 2026: actual -1.46, estimate -3, surprise +51.33%, Beat. Q4 2026, reported Nov 16, 2026: actual —, estimate -1.25, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates400.98K281.56K162.15K42.74KQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual 149.33K USD, estimate 375K USD, surprise -60.18%, Miss. Q2 2025, reported May 8, 2025: actual 50.28K USD, estimate 200K USD, surprise -74.86%, Miss. Q3 2025, reported Aug 14, 2025: actual 162.91K USD, estimate 300K USD, surprise -45.70%, Miss. Q4 2025, reported Nov 13, 2025: actual 145.38K USD, estimate 300K USD, surprise -51.54%, Miss. Q1 2026, reported Mar 31, 2026: actual 262.49K USD, estimate 125.88K USD, surprise +108.52%, Beat. Q2 2026, reported May 14, 2026: actual 145.95K USD, estimate 127.05K USD, surprise +14.88%, Beat. Q3 2026, reported Aug 13, 2026: actual 166.13K USD, estimate 132.58K USD, surprise +25.31%, Beat. Q4 2026, reported Nov 16, 2026: actual —, estimate 169K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$180

14776.03% upside
Past 12 months12-month forecastHigh $180Average $180Low $180

Rating distribution

5 ratings
Strong buy00%
Buy240%
Hold360%
Sell00%
Strong sell00%

CODX news

prnewswire.com

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT SALT LAKE CITY, Aug. 18, 2026 /PRNewswire/ -- Co-Diagnostics, Inc.…

Read source
seekingalpha.com

Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript

Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript

Read source
prnewswire.com

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-Enabled…

Read source
prnewswire.com

Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test

Submission includes a concurrent CLIA Waiver by Application for use of the test on the Co-Dx PCR Pro ® instrument in decentralized point-of-care settings SALT LAKE CITY, Aug. 6, 2026 /PRNewswire/ -- Co-Diagnostics, Inc.…

Read source
prnewswire.com

Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast

SALT LAKE CITY, July 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic…

Read source
prnewswire.com

Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies

Company also completes proof of concept for the first blood-borne test for Ebola on Co-Dx PCR Pro ® instrument SALT LAKE CITY, July 28, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"),…

Read source

CODX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CODX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
83.92K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research CODX

research.disclaimer